Does lower gut microbiome diversity increase systemic inflammation and cardiometabolic risk?

Reduced gut microbial diversity, characterized by low microbial gene richness, is a key biomarker of compromised metabolic health. This state initiates a distinct physiological cascade linking microbial ecology directly to systemic pathophysiology.

Pathological mechanisms

• Intestinal Dysbiosis: Low microbial diversity is marked by a depletion of beneficial short-chain fatty acid (SCFA)-producing taxa, such as Faecalibacterium and Roseburia, alongside an enrichment of pro-inflammatory, Gram-negative bacteria like Enterobacteriaceae.
• Barrier Impairment: Depletion of SCFA-producing bacteria deprives colonocytes of their primary energy source. This leads to the disruption of tight junction proteins (occludin and ZO-1) and triggers zonulin release, driving tight junction disassembly and paracellular leakage.
• Metabolic Endotoxemia: A compromised intestinal barrier permits the translocation of luminal lipopolysaccharides (LPS) and other bacterial products into the systemic circulation. These endotoxins bind to Toll-like receptor 4 (TLR4), initiating inflammatory cascades that elevate circulating biomarkers such as hsCRP, IL-6, and white blood cell (WBC) counts.

Clinical and cardiometabolic outcomes

• Cardiometabolic Risk: The resulting chronic, low-grade systemic inflammation directly impairs insulin signaling pathways and drives endothelial dysfunction. Large clinical cohorts consistently associate low microbial gene richness and these subsequent inflammatory processes with elevated phenotypes of obesity, insulin resistance, dyslipidemia, and cardiovascular disease.

Bottom line

• Bottom line: Lower gut microbiome diversity is a upstream driver of cardiometabolic risk, initiating a cascade from dysbiosis and tight-junction degradation to metabolic endotoxemia and systemic inflammation.